Therefore, the results of this study suggest that oncologist should subject these patients to more intensive monitoring of treatment response and consider other anti-HER2 treatments to improve the pCR rates for HER2 positive invasive micropapillary breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.